As of Aug 23
| -0.01 / -0.95%|
The 2 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +236.54% increase from the last price of 1.04.
The current consensus among 3 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.